AKT inhibitor AZD5363 suppresses stemness and promotes anti-cancer activity of 3,3′-diindolylmethane in human breast cancer cells
Author:
Funder
National Natural Science Foundation of China
Publisher
Elsevier BV
Subject
Pharmacology,Toxicology
Reference36 articles.
1. PD-L1 promotes OCT4 and Nanog expression in breast cancer stem cells by sustaining PI3K/AKT pathway activation;Almozyan;Int. J. Cancer,2017
2. Molecular insights into cancer drug resistance from a proteomics perspective;An;Exp. Rev. Proteom.,2019
3. Visualization and cellular hierarchy inference of single-cell data using SPADE;Anchang;Nat. Protoc.,2016
4. Cancer stem cell in breast cancer therapeutic resistance;Bai;Cancer Treat. Rev.,2018
5. Automated optimized parameters for T-distributed stochastic neighbor embedding improve visualization and analysis of large datasets;Belkina;Nat. Commun.,2019
Cited by 6 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Development of Novel Pyridine and Pyrimidine Clubbed Bisindoles as Inhibitors of AKT Pathway;ChemistrySelect;2024-07-17
2. Unraveling the dangerous duet between cancer cell plasticity and drug resistance;Computational and Systems Oncology;2023-08-15
3. Targeting mitochondrial dynamics by AZD5363 in triple-negative breast cancer MDA-MB-231 cell–derived spheres;Naunyn-Schmiedeberg's Archives of Pharmacology;2023-04-24
4. Preclinical and Clinical Trials of New Treatment Strategies Targeting Cancer Stem Cells in Subtypes of Breast Cancer;Cells;2023-02-24
5. Achieving a Deeper Understanding of Drug Metabolism and Responses Using Single-Cell Technologies;Drug Metabolism and Disposition;2023-01-10
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3